{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:13:14Z","timestamp":1791267194271,"version":"4.1.0"},"reference-count":63,"publisher":"Media Sphere Publishing House","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rus. Ann. Ophthal."],"published-print":{"date-parts":[[2025,3,6]]},"abstract":"<jats:p>Glaucoma is a chronic multifactorial neurodegenerative disease; the most studied local risk factors for glaucoma progression are elevated intraocular pressure (IOP) and its diurnal fluctuations. However, normalization of IOP does not always guarantee stabilization of the glaucomatous process. This article reviews data from international and Russian studies on the pathophysiological mechanisms underlying the development and progression of glaucomatous optic neuropathy, and discusses current approaches to its therapeutic management.<\/jats:p>","DOI":"10.17116\/oftalma202514101183","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T09:33:38Z","timestamp":1741253618000},"page":"83","source":"Crossref","is-referenced-by-count":3,"title":["Neuroprotective therapy of glaucoma"],"prefix":"10.17116","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6835-3393","authenticated-orcid":false,"given":"A.S.","family":"Vlasova","sequence":"first","affiliation":[{"name":"West Siberian Institute of Postgraduate Medical Education","place":["Tyumen, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1566-2299","authenticated-orcid":false,"given":"S.A.","family":"Petrov","sequence":"additional","affiliation":[{"name":"West Siberian Institute of Postgraduate Medical Education","place":["Tyumen, Russia"]},{"name":"Tyumen Scientific Center of the Siberian Branch of the Russian Academy of Sciences","place":["Tyumen, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2258-2207","authenticated-orcid":false,"given":"E.V.","family":"Renzyak","sequence":"additional","affiliation":[{"name":"West Siberian Institute of Postgraduate Medical Education","place":["Tyumen, Russia"]},{"name":"District Clinical Hospital of Khanty-Mansiysk Autonomous Okrug-Yugra","place":["Khanty-Mansiysk, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3679-8619","authenticated-orcid":false,"given":"T.N.","family":"Malishevskaya","sequence":"additional","affiliation":[{"name":"Helmholtz National Medical Research Center of Eye Diseases","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6743","reference":[{"key":"key-10.17116\/oftalma202514101183-1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-egsguidelines"},{"key":"key-10.17116\/oftalma202514101183-2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.08122"},{"key":"key-10.17116\/oftalma202514101183-3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31469-1"},{"key":"key-10.17116\/oftalma202514101183-4","unstructured":"World report on vision. World Health Organization. 2019. Accessed 10.12.2024.  https:\/\/cdn.who.int\/media\/docs\/default-source\/blindness-and-visual-impairment\/9789241516570-eng.pdf?sfvrsn=dd15adbb_3"},{"key":"key-10.17116\/oftalma202514101183-5","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000001068"},{"key":"key-10.17116\/oftalma202514101183-6","unstructured":"Resnikoff S, Pascolini D, Etya\u2019ale D, et al. Global data on visual impairment in the year 2002. Bull. Wld Hlth Org. 2004;(82):844-851"},{"key":"key-10.17116\/oftalma202514101183-7","doi-asserted-by":"publisher","DOI":"10.3109\/08"},{"key":"key-10.17116\/oftalma202514101183-8","doi-asserted-by":"publisher","DOI":"10.4103\/2008-322X.183"},{"key":"key-10.17116\/oftalma202514101183-9","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S67263"},{"key":"key-10.17116\/oftalma202514101183-10","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(01)01196-5"},{"key":"key-10.17116\/oftalma202514101183-11","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.086769"},{"key":"key-10.17116\/oftalma202514101183-12","unstructured":"Alekseev VN, Gazizova IR. Neurodegenerative changes in patients with primary open-angle glaucoma. Prakticheskaja medicina. 2012;(4):154-156 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-13","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2023.1290465"},{"key":"key-10.17116\/oftalma202514101183-14","doi-asserted-by":"publisher","DOI":"10.3390\/cells12091272"},{"key":"key-10.17116\/oftalma202514101183-15","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11050888"},{"key":"key-10.17116\/oftalma202514101183-16","unstructured":"Gazizova IR. Correction of mitochondrial dysfunction as the basis of neuroprotection in glaucoma. Oftal\u2019mologicheskie vedomosti. 2011;(4):64-69 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-17","doi-asserted-by":"publisher","DOI":"10.18008\/1816-5095-2019-4-479-48"},{"key":"key-10.17116\/oftalma202514101183-18","doi-asserted-by":"publisher","DOI":"10.1016\/s0039-6257(99)00027-2"},{"key":"key-10.17116\/oftalma202514101183-19","unstructured":"Teplov DB. Molecular Biology of Neurodegenerative Diseases Visions for the Future-Part B. Academic Press; 2021"},{"key":"key-10.17116\/oftalma202514101183-20","unstructured":"Egorov EA, Brezhnev AJu, Egorov AE. Neuroprotection in glaucoma: current opportunities and prospects. Klinicheskaja oftal\u2019mologija. 2014;(2): 108-112 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-21","unstructured":"Pervichnaja otkrytougol\u2019naja glaukoma. Nacional\u2019noe rukovodstvo. Eds Egorova EA, Kuroedova AV. Moscow: GEOTAR-Media; 2023 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-22","unstructured":"Kurysheva NI. Neiroprotektsiya i neiroregeneratsiya: perspektivy v lechenii glaukomy: monografiya. Moscow: Avtorskii tirazh; 2013 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-23","unstructured":"Usova LA, Harchenko LN, Chencova OB. Medikamentoznoe lechenie pervichnoj glaukomy: uchebnoe posobie. Moscow: MONIKI; 2014 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-24","unstructured":"Bezdetko PA. Neuroprotective treatment of glaucoma. Oftal\u2019mologija \u2014 nauka \u2014 praktika. 2014;17:26-27 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-25","unstructured":"Kurysheva NI. Secondary neuroprotection in glaucoma. Medicinskij sovet. 2008;(3-4):76-77 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2008.01459.x"},{"key":"key-10.17116\/oftalma202514101183-27","unstructured":"Veselovskaja ZF, Veselovskaja N.N. Primary neuroprotection in glaucoma. Klinicheskaja oftal\u2019mologija. 2011;(4):131-132 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-28","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(14)71458-8"},{"key":"key-10.17116\/oftalma202514101183-29","doi-asserted-by":"publisher","DOI":"10.1007\/BF02172889"},{"key":"key-10.17116\/oftalma202514101183-30","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101703"},{"key":"key-10.17116\/oftalma202514101183-31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2016.04.032"},{"key":"key-10.17116\/oftalma202514101183-32","unstructured":"Irshad M, Chaudhuri PS. Oxidant-antioxidant system: role and significance in human body. Indian J Exp Biol. 2002;40(11):1233-1239"},{"key":"key-10.17116\/oftalma202514101183-33","unstructured":"Korshunova AB, Prosvirkina IA. Prospects for the use of mexidol in ischemic and metabolic disorders. Bjulleten\u2019 jeksperimental\u2019noj biologii i mediciny. 2012;(1):257-326 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-34","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro201811812287"},{"key":"key-10.17116\/oftalma202514101183-35","unstructured":"Shchul\u2019kin AV. Effect of mexidol on the development of the phenomenon of the neuronal excitotoxicity in vitro. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;112(2):35-39 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-36","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma2022138051126"},{"key":"key-10.17116\/oftalma202514101183-37","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20171173255-65"},{"key":"key-10.17116\/oftalma202514101183-38","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20211211117"},{"key":"key-10.17116\/oftalma202514101183-39","unstructured":"Bratko VI. Combined treatment of ophthalmopathology with the use of Mexidol. Bjulleten\u2019 jeksperimental\u2019noj biologii i mediciny. 2012;(1):232-236 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-40","unstructured":"Egorov EA, Obruch BV, Oleinik AI, et al. The use of the drug Mexidol in patients with dystrophic diseases of the posterior segment of the eye. Klinicheskaya oftal\u2019mologiya. 2009;10(4):145-148 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-41","unstructured":"Egorov EA, Davydova NG, Romanenko IA, et al. Mexidol in complex treatment of glaucoma. Klinicheskaya oftal\u2019mologiya. 2011;12(3):107-111 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-42","unstructured":"Egorov EA, Gvetadze AA, Davydova NG. Antioxidant agents in neuroprotection treatment of glaucoma. Russian Annals of Ophthalmology=Vestnik oftal\u2019mologii. 2013;129(2):67-69 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-43","unstructured":"Bolatbekova AN, Kopbaeva DE, Arinova AI, et al. Evaluation of the effectiveness of Mexidol in the complex treatment of glaucoma neuropathy. Gigiena truda i medicinskaja jekologija. 2015;2(47):67-77 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-44","unstructured":"Volchegorskij IA, Tur EV, Soljannikova OV, et al. The effect of a water-soluble antioxidant drug (mexidol) on the sensitivity of the optic nerve and the rate of blood flow in the arteries of the eyeball and orbit in patients with primary open-angle glaucoma. Russian Annals of Ophthalmology=Vestnik oftal\u2019mologii. 2012;(4):35-37 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-45","unstructured":"Malyshev VE, Sal\u2019nikova OI. The experience of using the drug \u201cMexidol\u201d in the complex outpatient treatment of patients with eye diseases of degenerative-dystrophic origin. Bjulleten\u2019 eksperimental\u2019noy biologii i meditsiny. 2006;(1):55-57 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-46","unstructured":"Dorofeev DA. The use of antioxidant therapy in the complex treatment of primary open-angle glaucoma. In: III Scientific and Practical Olympiad \u201cMexidol: 20 years in clinical practice\u201d. Prilozhenie k zhurnalu \u201cTerapiya\u201d. Moscow: Bionika Media; 2019 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-47","unstructured":"Afonina EA, Levko MA, Chekurova LV, et al. Our experience of using mexidol in the complex treatment of patients with primary open-angle glaucoma. In: Russian glaucoma school. Conference \u201cGlaucoma: theory and practice\u201d. St. Petersburg: Chelovek i ego zdorov\u2019e; 2013;8:33-37 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-48","unstructured":"Loskutov IA, Andrjuhina OM, Kovrizhkina AA. The use of Mexidol in the treatment of primary open-angle glaucoma. Effektivnaya farmakoterapiya. 2022;18(11):52-56 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-49","doi-asserted-by":"crossref","unstructured":"Leonova ES, Poljakov SV, Pozdnjakova MA, et al. The experience of neuroprotective therapy of primary open-angle glaucoma based on the use of various forms of Mexidol. Russian Annals of Ophthalmology=Vestnik oftal\u2019mologii. 2015;(6):90-93 (In Russ.)","DOI":"10.17116\/oftalma2015131691-94"},{"key":"key-10.17116\/oftalma202514101183-50","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma202313904135"},{"key":"key-10.17116\/oftalma202514101183-51","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma202414004148"},{"key":"key-10.17116\/oftalma202514101183-52","unstructured":"Klinicheskie rekomendacii \u00abGlaukoma pervichnaja otkrytougol\u2019naja\u00bb. 2024. Accessed 10.12.2024 (In Russ.). https:\/\/cr.minzdrav.gov.ru\/preview-cr\/96_2"},{"key":"key-10.17116\/oftalma202514101183-53","unstructured":"Klinicheskie rekomendacii \u201cGlaukoma pervichnaja zakrytougol\u2019naja\u201d. 2024. Accessed 10.12.2024 (In Russ.). https:\/\/cr.minzdrav.gov.ru\/preview-cr\/631_2"},{"key":"key-10.17116\/oftalma202514101183-54","unstructured":"Alekseev IB, Ignat\u2019ev SA, Vorob\u2019eva IV, et al. Lechenie glaukomnoi opticheskoi neiropatii metodom endonazal\u2019nogo elektroforeza Korteksina: uchebno-metodicheskoe posobie. Moscow: RMAPO; 2014 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-55","unstructured":"Trofimova SV, Maksimov IB, Neroev VV. Regulyatornoe deistvie peptidov setchatki. St. Petersburg: Foliant; 2004 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-56","doi-asserted-by":"publisher","DOI":"10.52485\/19986173_2022_4_98"},{"key":"key-10.17116\/oftalma202514101183-57","doi-asserted-by":"crossref","unstructured":"Astahov JuS, Butin EV, Morozova NV, et al. The experience of using Retinalamine in the treatment of glaucoma neuroopticopathy and age-related macular degeneration. Oftal\u2019mologicheskie vedomosti. 2013;5(2):45-49 (In Russ.)","DOI":"10.17816\/OV2013245-49"},{"key":"key-10.17116\/oftalma202514101183-58","unstructured":"Alekseev VN, Churilina NJu, Pavlova EA. Morphometric substantiation of the neuroprotective effect of peptides in primary open-angle glaucoma. Uspehi sovremennogo estestvoznanija. 2008;(2):89-91 (In Russ.)"},{"key":"key-10.17116\/oftalma202514101183-59","doi-asserted-by":"publisher","DOI":"10.17116\/oftalma202013605158"},{"key":"key-10.17116\/oftalma202514101183-60","doi-asserted-by":"publisher","DOI":"10.1006\/exer.2000.0822"},{"key":"key-10.17116\/oftalma202514101183-61","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2005.21.175"},{"key":"key-10.17116\/oftalma202514101183-62","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.6.797"},{"key":"key-10.17116\/oftalma202514101183-63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2010.09.026"}],"container-title":["Russian Annals of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T09:34:22Z","timestamp":1741253662000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/vestnik-oftalmologii\/2025\/1\/10042465X2025011083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3,6]]}},"alternative-id":["10.17116\/oftalma202514101183"],"URL":"https:\/\/doi.org\/10.17116\/oftalma202514101183","relation":{},"ISSN":["0042-465X"],"issn-type":[{"value":"0042-465X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,6]]}}}